CVS Health Corp vs ProShares UltraPro QQQ ETF — how do they compare? CVS Health Corp trades at $87.21 (market cap $112.29B), while ProShares UltraPro QQQ ETF trades at $80.94 (market cap $38.74B). The key difference: CVS Health Corp is far larger — about 2.9× ProShares UltraPro QQQ ETF's market cap, and CVS Health Corp pays a 3.03% dividend while ProShares UltraPro QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and ProShares UltraPro QQQ ETF for 24 Days on average.
| CVS | TQQQ | |
|---|---|---|
Market Cap | $112.29B | $38.74B |
Volume | 7,763,676 | 65,384,797 |
Sector | Health | Leveraged / Inverse |
52-Week High | $110.60 | $87.22 |
52-Week Low | $70.08 | $37.89 |
Typical Hold Time | 83 Days | 24 Days |
Enterprise Value | $174.64B | — |
Dividend Yield | 3.03% | — |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
TQQQ trades at $80.67, down 3.5% in the last session amid mixed technical signals. The ETF maintains a bullish overall technical rating with strong moving average support but faces neutral oscillators. Recent news highlights significant hidden costs beyond the stated 0.82% expense ratio, including financing charges that impact returns. Institutional activity shows mixed positioning with some firms reducing stakes while others add exposure.
Outlook remains volatile given TQQQ's 3x leveraged structure, which amplifies both gains and losses. The ETF faces headwinds from volatility decay and hidden costs, though AI-driven tech growth provides underlying support. Key risks include amplified drawdowns during market corrections and structural costs that erode long-term performance versus the underlying index.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →